Media stories about Joint (NASDAQ:JYNT) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Joint earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.6924917970625 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

JYNT has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Joint from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Wednesday, September 27th. ValuEngine raised shares of Joint from a “sell” rating to a “hold” rating in a research note on Sunday. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Joint presently has an average rating of “Buy” and a consensus price target of $5.86.

Shares of Joint (JYNT) traded up $0.09 during mid-day trading on Thursday, reaching $4.99. 31,800 shares of the company’s stock were exchanged, compared to its average volume of 25,600. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.21. Joint has a one year low of $2.62 and a one year high of $6.00. The stock has a market capitalization of $66.24, a P/E ratio of -7.23 and a beta of 1.53.

Joint (NASDAQ:JYNT) last issued its earnings results on Thursday, November 9th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. Joint had a negative net margin of 36.74% and a negative return on equity of 98.28%. The company had revenue of $6.55 million for the quarter, compared to the consensus estimate of $6.28 million. analysts anticipate that Joint will post -0.27 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at

About Joint

The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.

Insider Buying and Selling by Quarter for Joint (NASDAQ:JYNT)

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with Analyst Ratings Network's FREE daily email newsletter.